AML Video Channel
Explore the latest insights and summaries from experts in AML.
Therapeutic Agents
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Emerging Treatment Options for AML in 2024
FEATURING
Alexander Perl
- 723 views
- March 3, 2024
- 4
Indy Hematology Review
R/R AML: Current, Emerging, and Targeted Therapies
FEATURING
Rami Komrokji
- 351 views
- April 22, 2024
- 3
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Immunotherapies in Acute Leukemias: 2024 Update
FEATURING
Catherine Lai
- 536 views
- March 11, 2024
- 3
SOHO Brazil 2024
Where I Use Azacitidine and Venetoclax in AML: Present and Future
FEATURING
Jeffrey Lancet
- 471 views
- July 11, 2024
- 4
Icahn School of Medicine at Mount Sinai
BPDCN: Current and Future Directions
FEATURING
Naveen Pemmaraju
- 489 views
- May 31, 2024
- 2
Rush University Medical Center
Management of Viral Infections Post-Transplant: CMV, EBV, and HHV-6
FEATURING
Eric Bhaimia
- 339 views
- May 24, 2024
Indy Hematology Review
HSCT in 2024: What Every Hematologist Needs to Know
FEATURING
Richard Childs
- 752 views
- April 18, 2024
- 5
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignancies
FEATURING
Ruemu Birhiray
- 908 views
- April 16, 2024
- 5
Moffitt Cancer Center
Using Transplant in Patients With p53 Mutant MDS or AML
FEATURING
Hany Elmariah
- 330 views
- March 7, 2024
- 5
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Debates in AML: 7+3 Is No Longer the Standard of Care
FEATURING
Tapan Kadia
- 682 views
- September 11, 2024
- 8
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: AML
FEATURING
Farhad Ravandi
- 384 views
- March 25, 2024
- 2
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: FLAG-IDA + Venetoclax in Newly Diagnosed or R/R AML
FEATURING
Wei-Ying Jen
- 246 views
- June 26, 2024
- 2
University of Miami Sylvester Comprehensive Cancer Center
Role of Mutations in AML: FLT3-ITD Mutation Confers Poor Prognosis but is Actionable
FEATURING
Sangeetha Venugopal
- 187 views
- March 18, 2024
- 1
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: FLAG-GO vs. FLAG-IDA in Untreated Core Binding Factor AML
FEATURING
Gautam Borthakur
- 150 views
- July 1, 2024
- 2
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Management of AML in Older Patients
FEATURING
Farhad Ravandi
- 199 views
- August 29, 2024
Rush University Medical Center
What is New in AML: Risk Classification, Germline Mutations, and Targeted Therapies
FEATURING
Ehab Atallah
- 231 views
- May 29, 2024
- 1
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Real-World Data From R/R BPDCN Treated With Tagraxofusp
FEATURING
Emanuele Angelucci
- 216 views
- July 23, 2024
- 1
SOHO Brazil 2024
The Gold Standard in the Use of FLT3 and IDH Inhibitors in AML
FEATURING
Jeffrey Lancet
- 136 views
- July 11, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: QuANTUM-First Trial - Newly Diagnosed FLT3-ITD+ AML Patients Receiving Chemo + Quizartinib vs. Placebo
FEATURING
Esther Oliva
- 129 views
- June 28, 2024
Yale Cancer Center
The Role of Hypomethylating Agent Maintenance in AML
FEATURING
Rory Shallis
- 117 views
- July 1, 2024
University of Miami Sylvester Comprehensive Cancer Center
Current and Emerging Treatment Approaches for Patients With AML or MDS
FEATURING
Sangeetha Venugopal
- 132 views
- August 26, 2024
Insights from 2023 ASH Annual Meeting
FLT3-ITD Mutated AML: PROs From the QuANTUM-First Trial of Quizartinib vs. Standard Chemo
FEATURING
Esther Oliva
- 152 views
- March 22, 2024
MyCancerHaven
Experts Discuss the Role of Stem Cell Transplant in AML
FEATURING
Ravi Vij,
Muzaffar Qazilbash
- 114 views
- April 11, 2024
- 1
MyCancerHaven
Experts Discuss How to Approach Frontline Treatment of Unfit Patients With AML
- 105 views
- May 22, 2024
Scripps Health
Managing Intensive-Chemotherapy Ineligible Patients With AML
FEATURING
Courtney D. DiNardo
- 161 views
- March 20, 2024
- 2
Yale Cancer Center
Summary of Promising Recent Studies in LR-MDS, HR-MDS, and R/R AML
FEATURING
Rory Shallis
- 91 views
- May 16, 2024
ecancer
EHA 2024 Insights: APOLLO Trial Summary - ATRA + ATO vs. Standard ATRA + Chemo in High-Risk APL
FEATURING
Uwe Platzbecker
- 92 views
- July 24, 2024
Indy Hematology Review
Current & Emerging Therapies for AML and MDS
FEATURING
Rami Komrokji
- 150 views
- May 3, 2024
- 1
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: QUAZAR AML-001 - Oral Azacitidine Maintenance in AML Pts With Myelodysplasia-Related Changes
FEATURING
Maria Teresa Voso
- 87 views
- June 20, 2024
Yale Cancer Center
Targeting Apoptosis in Leukemia: Lessons and Challenges
FEATURING
Marina Konopleva
- 110 views
- March 15, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: AML Highlights - Focus on Menin Inhibitors
FEATURING
Joshua Zeidner
- 68 views
- June 26, 2024
Icahn School of Medicine at Mount Sinai
Therapeutic Targeting of RNA Splicing Factor Mutant Leukemias
FEATURING
Omar Abdel-Wahab
- 57 views
- July 2, 2024
UNC Lineberger Comprehensive Cancer Center
Strategies for Managing Toxicities of Oral Oncolytics in Leukemia
- 57 views
- August 28, 2024
Moffitt Cancer Center
Optimal Use of Targeted Therapy for the Elderly or Unfit AML Patient
FEATURING
Onyee Chan
- 109 views
- March 5, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Debates in AML: 3+7 is the SOC Induction Therapy for AML
FEATURING
Ant Uzay
- 56 views
- August 15, 2024
- 1
Louisville Hematology Highlights
New Directions in CAR-T: Targeting Novel Antigens
FEATURING
Robert Emmons
- 146 views
- February 27, 2024
- 2
Louisville Hematology Highlights
Is a Bigger Induction "Hammer" Necessarily Better in Today's Stem Cell Transplantation?
FEATURING
William Tse
- 110 views
- February 27, 2024
- 1
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Future Directions in AML: Optimizing Doublets and Triplets to Improve Efficacy and Maintain Safety
FEATURING
Naval Daver
- 58 views
- February 15, 2024